National Guard Health Affairs

King Saud Bin Abdulaziz University for Health Sciences

King Abdullah International Medical Research Center

King Abdullah Inetrnational Medical Research Center

Mohamed Boudjelal

Atef Nehdi

Imadul Islam

Ahmed Alaskar

Rabih Omran Al-Kaysi

Rizwan Ali

Ahmed Al Askar

Alshaimaa Alhallaj

Hina Rehan

Sabhi Rahman

Gamal Edin Gmati

Bandar Alghanem

Khadega A Abuelgasim

Hajar Mohammed Alzahrani

Compounds, methods of synthesis, and methods of cancer treatment by arylidene-1,3-dioxane-4,6-diones. A Meldrum's acid-based chemistry and hybrid solid-liquid method. The method includes protection of ketone and aldehyde components and simultaneous immobilization on the solid phase, introduction of substituents, grafts and derivatives compatible with the protection, detachment and restoration of active carbonyl reactivity, reaction of ketone library with malonate, reacting of the products with the aldehyde library in liquid phase and separation of the products by preparative HPLC.

Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof

The invention is directed to a method for treating a cancer patient by administering an agent that depletes intracellular ATP along with a purine analog, such as fludarabine. It is also directed to a method for selecting a patient having cancer cells susceptible to depletion of their intracellular ATP.

Methods for treating cancer using purine analogs by depleting intracellular ATP

The present disclosure relates to methods of reducing the number of abnormal PBMC cells in a leukemia patient. The methods may include administering an effective amount of a drug, which may not be indicated for leukemia, or an antibody-drug conjugate. The antibody-drug conjugate includes an antibody selected from the group consisting of an anti-&#x3b1;-adrenoreceptor antibody, an anti-&#x3b2; adrenoceptor antibody, an anti-trace amine-associated receptor 1 antibody, an anti-dopamine receptor antibody, and an anti-serotonin receptor antibody; a drug selected from the group consisting of isoproterenol, methyldopa, olanzapine, and a derivative thereof; and a linker that conjugates the antibody and the drug.

Method for treating leukemia

A method of treating leukemia in a patient, the method including obtaining a plasma sample from a patient at a first time point and at a second time point, measuring a gene expression level of a set of core clock genes, and at least one of a first set of peripheral clock genes and a second set of peripheral clock genes, each in the plasma sample at the first time point and in the plasma sample at the second time point. Then determining that a first treatment is effective or ineffective for the patient when a correlation of the gene expression level of the set of core clock genes, the first set of peripheral clock genes, and the second set of peripheral clock genes, and treating the patient accordingly.

Method of treating leukemia based on gene expression of clock genes

Growing community of inventors

Riyadh, Saudi Arabia

Mohamed Boudjelal